

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****Importer of Controlled Substances;  
Notice of Registration; R & D Systems,  
Inc.**

By Notice dated August 17, 2012, and published in the **Federal Register** on August 20, 2012, 77 FR 50162, R & D Systems, Inc., 614 McKinley Place NE., Minneapolis, Minnesota 55413, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Drug	Schedule
1-Pentyl-3-(1-naphthoyl)indole (7118).	I
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (7297).	I
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I
3,4-Methylenedioxymethamphetamine (7405).	I
Dimethyltryptamine (7435) .....	I
Amphetamine (1100) .....	II
Methylphenidate (1724) .....	II
Phencyclidine (7471) .....	II
Cocaine (9041) .....	II
Oxycodone (9143) .....	II
Thebaine (9333) .....	II
Fentanyl (9801) .....	II

The company plans to import the listed controlled substances in dosage form to distribute to researchers.

In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of R & D Systems, Inc., to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated R & D Systems, Inc., to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance

with 21 CFR § 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: January 15, 2013.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.*

[FR Doc. 2013-01554 Filed 1-24-13; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****Importer of Controlled Substances,  
Notice of Registration, Myoderm**

By Notice dated June 28, 2012, and published in the **Federal Register** on July 5, 2012, 77 FR 39741, Myoderm, 48 East Main Street, Norristown, Pennsylvania 19401, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Drug	Schedule
Amphetamine (1100) .....	II
Lisdexamfetamine (1205) .....	II
Methylphenidate (1724) .....	II
Pentobarbital (2270) .....	II
Nabilone (7379) .....	II
Codeine (9050) .....	II
Oxycodone (9143) .....	II
Hydromorphone (9150) .....	II
Hydrocodone (9193) .....	II
Levomethorphan (9210) .....	II
Meperidine (9230) .....	II
Methadone (9250) .....	II
Methadone intermediate (9254) ...	II
Morphine (9300) .....	II
Oxymorphone (9652) .....	II
Fentanyl (9801) .....	II

The company plans to import the listed controlled substances in finished dosage form for clinical trials, and research.

The import of the above listed basic classes of controlled substances is granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage form for commercial distribution in the United States.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that the registration of Myoderm, to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA

has investigated Myoderm, to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: January 15, 2013.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of  
Diversion Control, Drug Enforcement  
Administration.*

[FR Doc. 2013-01540 Filed 1-24-13; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE****Drug Enforcement Administration****Importer of Controlled Substances;  
Notice of Registration; Chattem  
Chemicals, Inc.**

By Notice dated June 28, 2012, and published in the **Federal Register** on July 6, 2012, 77 FR 40086, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Drug	Schedule
Methamphetamine (1105) .....	II
4-Anilino-N-phenethyl-4-piperidine (8333).	II
Phenylacetone (8501) .....	II
Opium, raw (9600) .....	II
Poppy Straw Concentrate (9670) .....	II
Tapentadol (9780) .....	II

The company plans to import the listed controlled substances to manufacture bulk controlled substances for sale to its customers.

The company plans to import an intermediate form of Tapentadol (9780), to bulk manufacture Tapentadol for distribution to its customers.

Comments and requests for hearing on applications to import narcotic raw material are not appropriate, 72 FR 3417(2007).

Regarding all other basic classes of controlled substances, no comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a), and determined that